Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration—Evidence supporting practice change [Biological Sciences]

Vickers (1) offers little substantive criticism, but we address three items he mentions: (i) our choice of clinical endpoint, (ii) the potential for multiple-testing false positives, and (iii) the need for additional study. An important distinction of our study (2) is the use of neovascular AMD (nvAMD) as the endpoint....

https://ift.tt/2JRKwOr